Senores Pharmaceuticals share price listed at ₹600, a premium of 53% over its IPO price of ₹391 on the NSE in trade on Monday, December 30. Meanwhile, the stock debuted at a premium of 51.8% at ₹593.70 on the BSE.
The subscription status and grey market premium had indicated strong listing gains for Senores Pharmaceuticals’ share price, which saw its public issue open on December 20, 2024, and end on December 24, 2024.
Senores Pharmaceuticals IPO was subscribed 97.86 times, with 93.16 times subscription in the retail category, 97.84 times in the QIB category, and 100.35 times in the NII category.
Senores Pharmaceuticals IPO grey market premium or the GMP stood at + 284 as per Investorgain.co. The same meant Senores Pharmaceuticals shares were being traded in the grey market at ₹284 above the issue price. It also meant that the market participants were anticipating the listing of Senores Pharmaceuticals share price at ₹675, with listing gains of 72.63% over the issue price.
Senores Pharmaceuticals IPO price band had been set at ₹372 to ₹391 per share and listing of shares was well above the upper price band of the issue price
Senores Pharmaceuticals IPO was a book-built issue of ₹582.11 crore. The issue was a mix of fresh issue of 1.28 crore shares, aggregating to ₹500 crore and an offer for sale of 0.21 crore shares, worth ₹82.11 crore.
Senores Pharmaceuticals was founded in December 2017 and primarily develops and produces pharmaceutical goods for the regulated markets of the United States, Canada, and the United Kingdom, but it also serves emerging nations.
Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Tablets, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets, Topiramate Capsules, and Ivermectin Tablets are among the company’s product line.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions.
